Logo Prima Biomed

Welcome to the Newsroom

18 November 2015

Prima BioMed unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor



- Prima to run a Phase I safety and dose finding study of IMP321 in combination with a
checkpoint inhibitor in metastatic melanoma in Australia
- Potentially revolutionary study in immuno-oncology by combining APC activator with
checkpoint inhibitor
- The Human Research Ethics Committee at the Greenslopes Private Hospital in Queensland
has cleared the study protocol
- First patient expected to enter study in early 2016